Equine Viral Arteritis: Virus and Disease Reference

Overview and Taxonomy of Equine Arteritis Virus (EAV): Classification and Virion Structure

The Equine Arteritis Virus (EAV) stands as the archetypal member of the family Arteriviridae, a group of enveloped, positive-sense single-stranded RNA (+ssRNA) viruses that occupy a distinctive niche within the order Nidovirales [10, 15, 17]. This taxonomic placement, shared with the Coronaviridae, Mesoniviridae, and Roniviridae families, is predicated on a shared genome organization and a conserved replication strategy that involves the production of a nested set of subgenomic mRNAs, a hallmark of the nidovirus order [10, 17]. Understanding the precise classification and intricate virion architecture of EAV is not merely an academic exercise; it is foundational to deciphering the molecular mechanisms of pathogenesis, host range, and immune evasion that underpin the disease state known as Equine Viral Arteritis (EVA), a condition of significant economic and sanitary concern for the global equine industry [1, 12, 14].

Taxonomic Position and Nomenclature

Historically, EAV was considered the prototype species of the family Arteriviridae. However, advances in phylogenetic and genomic analyses have led to a refined taxonomic structure. Contemporary classification places EAV within the subfamily Equarterivirinae, genus Alphaarterivirus, with the formal species designation being Alphaarterivirus equid [1, 10]. This reclassification reflects the unique evolutionary trajectory of EAV relative to other arteriviruses, such as the porcine reproductive and respiratory syndrome virus (PRRSV). The virus demonstrates a single, albeit highly variable, serotype, yet exhibits marked heterogeneity in virulence among circulating strains, ranging from avirulent to highly pathogenic variants [15, 16]. This phenotypic diversity is encapsulated within a genotypic framework that has been delineated through extensive molecular epidemiology, identifying multiple phylogroups (e.g., European phylogroup D) that circulate in specific geographic regions and over particular timeframes [2]. The genetic characterization of field strains, such as those isolated during the 2019 UK outbreaks, has confirmed their clustering within established phylogroups while also revealing unique polymorphisms, including a previously unreported truncation in the GP4 glycoprotein [2]. The World Organisation for Animal Health (WOAH) classifies EAV as a notifiable pathogen, underscoring the virus's capacity to disrupt international trade and breeding programs through its establishment of a long-term carrier state in stallions [1, 13, 14].

Genome Architecture and Organization

The EAV genome is a linear, infectious, positive-sense single-stranded RNA molecule of approximately 12.7 kilobases (kb) in length, exclusive of the 3' polyadenylated tail [10, 15]. This compact genome is organized into at least ten functional open reading frames (ORFs). The 5'-proximal three-quarters of the genome is occupied by two large ORFs, ORF1a and ORF1b, which encode the viral replicase polyproteins, pp1a and pp1ab. The latter is expressed via a -1 ribosomal frameshift mechanism at a conserved slippery sequence located between ORF1a and ORF1b, a strategy common to nidoviruses [15]. These large polyproteins are co- and post-translationally cleaved by viral proteases to yield at least 13 non-structural proteins (nsps), including nsp1, nsp2, and the multi-functional nsp10. The nsp10 protein, a helicase, has been shown to play a critical role in antagonizing host innate immunity by mediating the proteasomal degradation of the mitochondrial antiviral-signaling protein (MAVS) through the recruitment of E3 ubiquitin ligases Smurf1 and MARCH5 [4]. The 3'-proximal one-third of the genome encodes the structural proteins, transcribed from a nested set of subgenomic mRNAs. This region encompasses ORF2a, ORF2b, ORF3, ORF4, ORF5, ORF6, and ORF7, which specify the envelope proteins GP2 (formerly GP2a/GP2b or GP2/GP3), GP3, GP4, GP5, the membrane protein M, and the nucleocapsid protein N, respectively [10, 11, 15]. The genetic variability within the structural protein-coding regions, particularly ORF3 encoding GP3 and ORF5 encoding GP5, is a major driver of antigenic diversity and has been implicated in the adaptation of the virus during persistent infection in the stallion reproductive tract [11].

Virion Morphology and Structural Proteins

EAV virions are small, spherical, and enveloped, with a diameter of approximately 50 to 70 nanometers [10, 17]. The viral envelope, derived from host cell membranes, is a lipid bilayer decorated with a constellation of viral glycoprotein spikes that are essential for host cell attachment and entry. Unlike many other arteriviruses that utilize the macrophage-specific receptor CD163, EAV has been demonstrated to employ the broadly expressed plasma membrane tetraspanin CD81 as a critical entry receptor [3]. This represents a significant receptor switch within the Arteriviridae family and explains the expanded cellular tropism of EAV, which can infect not only macrophages but also endothelial cells, fibroblasts, and CD3+ T lymphocytes [3, 5, 9].

The structural protein complement is composed of seven proteins, each with a defined role in virion biogenesis and infectivity. The major envelope proteins are GP5 and the non-glycosylated membrane protein M. GP5 and M form disulfide-linked heterodimers that are essential for virus assembly and budding. The M protein is the most conserved structural protein, while GP5 is a primary target for virus-neutralizing antibodies [15, 17]. The minor envelope proteins, GP2, GP3, and GP4, form a heterotrimeric complex that is incorporated into the virion at lower copy numbers but is indispensable for virus entry. The GP4 protein, in particular, has been a focus of recent genetic characterization, with a unique truncation at position 149 identified in a UK outbreak strain, a feature not previously described in any arterivirus [2]. The presence and integrity of these minor glycoproteins are critical for the efficient interaction with the CD81 receptor, and variations in these proteins can influence cell tropism and virulence [3]. Inside the envelope lies the helical nucleocapsid, composed of the phosphorylated nucleocapsid (N) protein tightly complexed with the genomic RNA [15]. The N protein is highly immunogenic and serves as the primary antigen for serological detection methods, such as the virus neutralization test (VNT) and enzyme-linked immunosorbent assays (ELISA) [1, 7, 8].

The Role of Non-Structural Proteins and the Replication Complex

Beyond the structural components, the non-structural proteins orchestrate the intracellular replication and transcription of the viral genome. The replication/transcription complex (RTC) is assembled from the cleaved products of the replicase polyproteins and is associated with modified intracellular membranes, likely of endosomal or autophagosomal origin. Among these nsps, nsp10 (the helicase) has emerged as a multi-functional protein of particular interest. Recent investigations have revealed that, beyond its role in RNA unwinding, nsp10 directly antagonizes the host interferon (IFN) response. By interacting with and promoting the polyubiquitination and proteasomal degradation of MAVS, a central adaptor protein in the RIG-I-like receptor (RLR) signaling pathway, EAV effectively suppresses the induction of type I interferons [4]. This evasion mechanism, mediated by the recruitment of the host E3 ligases Smurf1 and MARCH5, is dependent on the dimerization of nsp10 via its zinc finger motifs [4]. This finding highlights the sophisticated molecular interplay between EAV and the host innate immune system, where the virus simultaneously triggers a cellular IFN response while actively dismantling the signaling machinery required for its amplification [4]. The nsp2-coding region of ORF1a is another hotspot for genetic variation during persistent infection, suggesting its potential role in host adaptation and immune modulation within the unique microenvironment of the stallion reproductive tract [11].

Determinants of Tropism and Virulence

The structural basis of EAV tropism is intrinsically linked to its receptor utilization. The identification of CD81, a tetraspanin expressed on nearly all nucleated cell types, as a functional receptor for EAV explains the broad tissue distribution of the virus in infected horses [3]. This contrasts sharply with macrophage-tropic arteriviruses like PRRSV, which depend on CD163. The critical interaction site for EAV has been mapped to the large extracellular loop of CD81, specifically the alpha helix “D” region, which is essential for viral entry [3]. The expression of CD81 on CD3+ T cells is a key determinant of the carrier state in stallions. A specific subpopulation of these T cells, which expresses a susceptible allele of the equine chemokine receptor CXCL16 (CXCL16^S), is permissive to EAV infection in vitro. This phenotypic trait is strongly correlated with the establishment of a long-term persistent infection in the male reproductive tract [6, 9]. In contrast, stallions homozygous for the resistant CXCL16^R allele possess a CD3+ T cell subpopulation that is refractory to infection, conferring a significantly lower probability of becoming long-term carriers [6, 9]. This host genetic factor, alongside viral genetic determinants found in ORF3 and ORF5, provides a molecular framework for understanding why a variable proportion (10–70%) of infected stallions become persistent shedders, while others clear the infection [9, 11]. The interplay between the viral GP proteins, the CD81 receptor, and the CXCL16-dependent T-cell susceptibility underscores the complexity of EAV pathogenesis and the evolution of the virus during intrahost persistence.

Molecular Pathogenesis of EAV: Mechanisms of Replication, Cytopathicity, and Host Immune Evasion

Equine arteritis virus (EAV), the prototypic member of the family Arteriviridae within the order Nidovirales, is a small, enveloped, positive-sense single-stranded RNA virus whose 12.7-kb genome encodes ten functional open reading frames (ORFs) [10, 15]. The molecular pathogenesis of EAV is a multifaceted interplay between viral replication strategies, direct cellular injury, and sophisticated countermeasures against host innate and adaptive immunity. This section provides a deep, mechanistic dissection of these processes, integrating recent breakthroughs in receptor biology, viral evolution within the carrier state, and the molecular arms race between viral nonstructural proteins and host antiviral signaling.

Viral Entry and the Discovery of a Novel Receptor

The initial step in EAV pathogenesis is attachment and entry into susceptible host cells. For decades, the entry mechanism of EAV remained an enigma, as it was known to infect a broad range of cell types, including endothelial cells, macrophages, smooth muscle cells, and fibroblasts, yet it did not utilize the canonical arterivirus receptor CD163, which is predominantly expressed on macrophages [3, 16]. This paradox was resolved through a landmark genome-wide CRISPR knockout screen, which identified the plasma membrane tetraspanin CD81 as an essential host factor for EAV infection [3]. This discovery represents the first documented instance of receptor switching within the Arteriviridae family. While most arteriviruses, such as porcine reproductive and respiratory syndrome virus (PRRSV), rely on CD163, EAV has evolved to utilize CD81, a ubiquitously expressed molecule with a broad tissue distribution. This switch directly explains the expanded cellular tropism of EAV and its capacity to cause systemic, endotheliotropic disease [3, 16].

The mechanistic basis for this interaction was elegantly mapped using horse/possum CD81 chimeras, which revealed that the alpha helix "D" within the large extracellular loop (LEL) of CD81 is critical for EAV entry [3]. Genetic knockout of CD81 or pre-incubation of cells with soluble CD81 conferred complete protection against EAV infection, whereas transfection of the EAV genome directly into CD81-knockout cells bypassed the entry block, confirming that CD81 functions specifically at the entry stage [3]. This finding has profound implications for cross-species transmission barriers and the development of novel therapeutic interventions targeting the virus-receptor interface. The adoption of CD81 highlights a key evolutionary divergence: EAV, unlike its sister arteriviruses, has shed its dependence on a macrophage-specific receptor to gain access to a vast array of host cells, driving the severe vascular and reproductive pathology characteristic of equine viral arteritis (EVA) [3, 16].

Replication Dynamics and Cytopathicity

Following entry via CD81, the viral genomic RNA is released into the cytoplasm, where it serves as a template for translation of the large replicase polyproteins. The replication complex is assembled on modified intracellular membranes, and the virus employs a distinctive nested set of subgenomic mRNAs for expression of its structural proteins [15, 17]. The cytopathicity of EAV is highly strain-dependent and correlates strongly with the ability to replicate in primary target cells. Comparative studies have demonstrated that highly virulent and moderately virulent strains are readily distinguished from avirulent strains by their plaque morphology and cytopathogenicity in primary equine pulmonary artery endothelial cells (ECs), whereas all three strains replicate similarly and produce comparable cytopathic effects in the non-equine rabbit kidney (RK-13) cell line [16]. This difference underscores the importance of using relevant primary cell models to study pathogenesis. In ECs, the expression of the nucleocapsid (N) protein is detected significantly earlier in virulent strains, suggesting that rapid replication kinetics are a key determinant of virulence [16].

The ultimate outcome of productive EAV replication in multiple cell types is cell death, which occurs primarily via apoptosis. The pathway engaged, however, is cell-type dependent. In BHK-21, RK-13, and Vero cell lines infected with the Bucyrus reference strain, apoptosis is confirmed by morphological changes, DNA fragmentation, and the activation of caspases [18]. Specifically, RK-13 cells exhibit the fastest progression to apoptosis (48 hours post-infection), followed by Vero cells (72 hours) and BHK-21 cells (96 hours). Crucially, activation of the extrinsic pathway (caspase-8) and intrinsic pathway (caspase-9) varies by cell line; for example, caspase-8 is not detected in infected BHK-21 cells, while caspase-9 is universally activated [18]. This indicates that EAV can trigger both death-receptor-mediated and mitochondrial-mediated apoptotic cascades depending on the cellular context. The timing of apoptosis is also critical: while it is a direct consequence of viral replication, it also represents an innate defense mechanism that can limit viral production, as viral titers decline as apoptosis progresses [18]. This delicate balance between viral exploitation and host limitation is central to the pathogenesis of acute EVA.

Genetic Determinants of Persistence and Intrahost Evolution in the Stallion

A unique and economically devastating aspect of EAV pathogenesis is its ability to establish a long-term persistent infection in the reproductive tract of stallions, rendering them lifelong carriers without overt clinical signs [6, 9, 11]. This carrier state, which can affect up to 70% of infected stallions, is the primary mechanism for viral perpetuation in the equine population [8, 11]. The molecular basis for this phenomenon has been definitively linked to host genetics, specifically allelic variation in the equine orthologue of CXCL16 (EqCXCL16) [6, 9]. The EqCXCL16 protein exists as two major isoforms: EqCXCL16^S (susceptible) and EqCXCL16^R (resistant). These isoforms differ by four non-synonymous amino acid substitutions within the chemokine domain [9]. Stallions carrying at least one copy of the CXCL16^S allele possess a subpopulation of CD3+ T lymphocytes that are susceptible to EAV infection in vitro, and this phenotype is highly predictive of the establishment of long-term carrier status following natural infection [6, 9]. Conversely, horses homozygous for the CXCL16^R allele are resistant to both CD3+ T cell infection in vitro and the long-term carrier state in vivo [6, 9]. The mechanistic difference lies in the functionality of the protein: while both isoforms have equal chemoattractant potential, EqCXCL16^S possesses significantly higher scavenger receptor and adhesion properties, which are required for EAV to bind and infect these T cells [9].

The selective pressure within the stallion’s reproductive tract drives a non-stochastic evolutionary pattern in the viral genome. Deep sequencing of sequential EAV isolates from experimentally infected carrier stallions revealed that persistent infection is characterized by extensive genome-wide purifying selection, but with specific, critical regions undergoing diversifying pressure [11]. The majority of nucleotide substitutions accumulate within ORF1a (the nsp2-coding region), ORF3 (encoding GP3), and ORF5 (encoding GP5) [2, 11]. These regions encode the surface glycoproteins and a viral protease, respectively. The evolution of GP3, in particular, shows maximum variability among outbreak strains, and a unique truncation in GP4 at position 149 has been identified, a feature not previously seen in any arterivirus [2]. This intrahost evolution suggests that EAV must constantly adapt to the complex immunological and cellular environment of the male reproductive tract to maintain persistence, while the selective bottleneck at transmission to semen reduces population diversity [11]. The development of a TaqMan allelic discrimination qPCR assay for the CXCL16^S/r polymorphism now allows for the pre-pubertal screening of colts to identify those at highest risk of becoming carriers, enabling targeted vaccination strategies to prevent the establishment of this reservoir [6].

Molecular Mechanisms of Host Immune Evasion

EAV employs multiple, sophisticated strategies to subvert the host immune response, ensuring its survival and propagation. The most critical of these is the antagonism of the type I interferon (IFN) system. While EAV replication triggers the host’s innate immune sensors, leading to the activation of the mitochondrial antiviral-signaling protein (MAVS) and a downstream IFN-β response, the virus simultaneously and potently suppresses this signal [4]. This is accomplished by the viral nonstructural protein 10 (nsp10), which is an RNA helicase. For the first time in an arterivirus, nsp10 has been shown to have a direct antagonistic effect on the innate immune signaling pathway [4]. Mechanistically, nsp10 directly interacts with MAVS and recruits two specific cellular E3 ubiquitin ligases: Smurf1 and MARCH5. These ligases then polyubiquitinate MAVS, marking it for proteasomal degradation [4]. The degradation of MAVS effectively dismantles the signaling hub required for RIG-I-like receptor (RLR) signaling, thereby blunting the production of IFN-β and downstream interferon-stimulated genes (ISGs). This degradation is dependent on the dimerization of nsp10, which occurs through zinc finger motif interactions, and specific key residues (D249, S287, and S1/F39/N41) mediate the binding of nsp10 to MAVS, Smurf1, and MARCH5, respectively [4]. By targeting MAVS, the "switch" of antiviral signaling, EAV ensures that a robust antiviral state cannot be established in infected cells, allowing viral replication to proceed unhindered.

Beyond the intracellular innate immune evasion, EAV also directly cripples the adaptive immune response by targeting dendritic cells (DCs). Dendritic cells are the most potent antigen-presenting cells and are essential for initiating T cell responses. EAV infects both monocytes and monocyte-derived dendritic cells (MoDCs), with the most efficient replication occurring in mature MoDCs [5]. Infection with a virulent strain of EAV causes a significant downregulation of key surface molecules, including CD83 (a maturation marker) on mature DCs, and CD14 and CD163 on monocytes [5]. This modulation of the surface phenotype is accompanied by profound functional impairment. Infected MoDCs exhibit a severely reduced capacity for endocytosis and phagocytosis, and crucially, they lose their ability to stimulate T cell proliferation in mixed lymphocyte reactions [5]. This indicates that EAV actively inhibits the very cells that should be presenting viral antigens to the immune system. By suppressing DC function, EAV creates a window of immunological blindness, delaying the onset of the adaptive immune response and facilitating its own spread. Ultimately, however, EAV replication in DCs leads to apoptosis-mediated cell death, a "scorched earth" tactic that eliminates the cellular machinery of immunity [5]. The combination of early functional paralysis and late killing of DCs, alongside the MAVS-mediated suppression of IFN signaling, creates a multi-layered immune evasion strategy that explains why clinical disease can be severe and why the virus can establish a persistent reservoir in the face of a neutralizing antibody response [5, 9].

Epidemiology of Equine Viral Arteritis: Global Seroprevalence, Risk Factors, and Transmission Dynamics

Equine viral arteritis (EVA), caused by the Alphaarterivirus equid (equine arteritis virus, EAV), is a notifiable infectious disease of significant sanitary and economic consequence to the global equine industry [1, 14]. The epidemiology of EAV is characterized by a complex interplay between viral persistence, host genetic susceptibility, and management practices that facilitate both horizontal and vertical transmission. Unlike many viral pathogens of livestock, the primary epidemiological driver of EAV is not a widespread, continuous circulation in the general population, but rather the establishment of a long-term carrier state in a subset of infected stallions, who serve as the sole natural reservoir for the virus [6, 9, 11]. This fundamental biological reality dictates the global seroprevalence patterns, the identification of specific risk factors, and the intricate dynamics of viral spread within and between equid populations. Understanding these epidemiological features is paramount for designing effective surveillance, control, and vaccination programs, as recognized by the World Organisation for Animal Health (WOAH), which lists EVA as a notifiable disease due to its potential for rapid international spread through the movement of infected equids and contaminated semen [1, 14].

Global Seroprevalence: A Heterogeneous and Regionally Variable Landscape

The seroprevalence of EAV in equids is strikingly heterogeneous across geographic regions, reflecting a complex mosaic of historical exposure, biosecurity protocols, vaccination practices, and population density. Large-scale serosurveys consistently demonstrate that EAV is not uniformly distributed; rather, it circulates at moderate to high levels within specific foci while remaining absent or at very low prevalence in others. A recent comprehensive cross-sectional study across western Europe, analyzing over 1,400 unvaccinated equids from 2011-2023, reported an overall seroprevalence of 9.7% (95% CI: 8.1-11.2%) using a commercial ELISA [1]. However, this aggregate figure masks profound regional differences. Seropositivity in Catalonia, northeastern Spain, was 15.6%, significantly higher than the 8.1% observed in Andalusia, southern Spain, and dramatically elevated compared to the 3.3% recorded in the southeastern United Kingdom [1]. This pattern suggests that localized factors, such as breeding density, the presence of carrier stallions, and historical outbreaks, rather than broad national-level factors, are the primary determinants of seroprevalence.

Similar regional variability is evident in other parts of Europe. In the Vojvodina region of Serbia, a serosurvey using the virus neutralization test (VNT) on 156 non-vaccinated horses revealed a staggering 21.15% seropositivity, with 9 out of 10 stud farms surveyed containing at least one seropositive animal [8]. This finding indicates a high level of active or recent viral circulation within that localized population, likely driven by management practices and the presence of undetected carrier stallions. In contrast, a study in the inner Aegean and Central Anatolia regions of Turkey found a moderate seroprevalence of 8.40% (95% CI: 5.61-12.39) in clinically normal horses from small family-type enterprises [7]. Further east, studies in Asia are less abundant but underscore the variability. Critically, the Orinoquia region of Colombia appears to be free of EAV, with a serosurvey of 100 horses from 11 municipalities yielding no positive results via VNT, suggesting that the virus remains exotic to that specific region, a status that rigorous import controls must protect [14, 19].

At the equid species level, while the majority of serological data comes from domestic horses (Equus caballus), evidence confirms EAV infection in donkeys and mules. The large European serosurvey reported anti-EAV antibody prevalence of 10.2% in horses, 7.7% in donkeys, and, notably, 6.4% in mules and hinnies, representing the first documented detection of EAV seropositivity in these hybrid equids in Europe [1]. Although the sample size for non-horse equids is often limited, these findings demonstrate that the host range for EAV extends beyond horses and that these species could potentially play a role in local transmission cycles, particularly in regions where they share grazing or breeding facilities. The reliance on serological tests, primarily ELISA for screening and VNT for confirmation, is critical for accurate prevalence estimation, as the VNT is considered the gold standard for detecting specific neutralizing antibodies, though cross-reactivity is not a concern given EAV's single serotype [8, 15].

Risk Factors for Seropositivity and Viral Persistence

The risk of EAV exposure and the subsequent establishment of infection are governed by a hierarchy of factors, ranging from broad environmental and management-level variables to specific host genetic determinants. These factors interact to create a complex risk profile for individual animals and populations.

Demographic and Management-Level Risk Factors

Among the variables analyzed in multivariate models, the geographic study region itself consistently emerges as the most significant risk factor, as it encapsulates a suite of underlying influences including local viral prevalence, breeding density, and management traditions [1]. Beyond region, specific management practices are strongly correlated with seropositivity. A study in Turkey identified participation in races and festivals as a significant risk factor (p<0.05), likely due to the commingling of horses from diverse origins and unknown health status, which facilitates direct or indirect contact [7]. This aligns with the observation that outbreaks are often reported in association with congregating events.

Age is another critical demographic factor. Seropositivity increases markedly with age, reflecting cumulative exposure over a lifetime. In the Turkish study, seroprevalence was only 2.47% in horses under 4 years of age but jumped to 11.05% in those over 4 years old (p=0.02) [7]. This pattern is consistent with a virus that does not circulate at a high enough rate to infect all horses as juveniles but rather poses a continuous, low-level risk of exposure throughout an animal's life. Interestingly, sex itself is not consistently a risk factor for seropositivity in the general population; mares and stallions are similarly likely to be exposed. However, the consequence of infection is profoundly sex-dependent. The role of biosecurity measures is also evident. The same Turkish study found that the absence of precautions taken against rodents and insects at enterprises was a significant risk factor [7], suggesting a potential, albeit poorly understood, role for mechanical or vector-borne transmission in certain contexts, though direct contact and aerosol are the primary routes. Conversely, the presence of a carrier stallion is arguably the most potent risk factor for a herd, as it ensures constant viral shedding and repeated exposure of all contact animals [13, 15, 20].

Host Genetic Susceptibility: The CXCL16 Paradigm

The most biologically compelling risk factor for EAV is the host's genetic makeup, specifically allelic variation in the CXCL16 gene. This discovery revolutionized the understanding of EAV epidemiology by explaining why only a subset of infected stallions become long-term carriers, despite uniform exposure [6, 9]. The equine orthologue of CXCL16 exists in two primary allelic forms: CXCL16^S (susceptible) and CXCL16^R (resistant), which differ by four non-synonymous nucleotide substitutions resulting in distinct protein isoforms [9]. The CXCL16^S protein can function as a receptor for EAV on a subpopulation of CD3+ T lymphocytes, rendering these cells susceptible to in vitro infection. In contrast, the CXCL16^R isoform, while retaining chemoattractant function, does not serve as an EAV receptor [9].

This functional difference has profound epidemiological consequences. Stallions that possess at least one copy of the CXCL16^S allele (genotypes CXCL16^S/S or CXCL16^S/R) are at significantly elevated risk of becoming long-term persistently infected (LTPI) carriers following natural infection [6, 9]. In contrast, stallions homozygous for the CXCL16^R allele (CXCL16^R/R) have a substantially lower probability of establishing the long-term carrier state [9]. The CXCL16^S allele appears to exert a dominant mode of inheritance, meaning a single copy is sufficient to confer increased susceptibility [9]. This has led to the development of a rapid TaqMan® allelic discrimination qPCR assay that can genotype prepubertal colts, identifying those carrying the susceptible genotype that would benefit most from early vaccination to prevent the establishment of the carrier state [6]. The CXCL16 genotype is, therefore, the most powerful predictor of which individual will become the epidemiological linchpin of EAV persistence, the carrier stallion. Recent genomic analysis of outbreak strains in the UK confirmed the presence of the heterozygous genotype (CXCL16^S/R) in four of five infected stallions, directly linking this genetic risk factor to ongoing transmission in a real-world outbreak scenario [2].

Transmission Dynamics: The Central Role of the Carrier Stallion

The transmission dynamics of EAV are fundamentally shaped by the unique biology of the virus within its natural host. While acute infection can lead to widespread shedding and clinical disease, the long-term perpetuation of EAV is almost entirely dependent on the persistent infection of the stallion's reproductive tract. This creates a transmission system with two distinct phases: a rapid, explosive acute phase and a chronic, insidious maintenance phase.

Routes of Transmission During Acute Infection

During the acute phase of infection, which typically lasts 2-3 weeks, EAV is shed via multiple routes, facilitating rapid spread among in-contact animals. The virus replicates extensively in the respiratory epithelium, leading to high titers in nasal secretions [11]. This allows for direct transmission via the aerosol or respiratory route, particularly under conditions of close confinement such as in stables, during transport, or at equine events. Concurrently, the virus is present in blood (buffy coat cells) and can be shed in urine and feces, although the relative importance of these routes is less well-defined. Venereal transmission from an acutely infected stallion to a mare is another critical acute-phase route, as the virus is present in semen at high concentrations very early after infection [2, 11]. Transplacental transmission leading to abortion is a hallmark of EAV infection, particularly in naive, seronegative mares exposed during the latter half of gestation, representing a vertical transmission event that is both devastating to the breeder and leads to a significant source of environmental contamination from fetal and placental tissues [10, 13].

The Carrier State: The Engine of Viral Perpetuation

The single most important driver of long-term EAV epidemiology is the establishment of the long-term carrier state in the stallion. Following natural EAV infection, 10-70% of infected stallions fail to clear the virus completely and become persistently infected, continuing to shed EAV in their semen for periods ranging from several months to a lifetime [6, 9, 11, 15]. The primary site of persistence is the ampullae of the vas deferens, and this persistence is associated with a robust but ultimately ineffective local inflammatory response [11]. The carrier stallion is the sole natural reservoir for EAV in the equid population [11]. This has profound implications for transmission dynamics. Unlike acute infections, which are self-limiting, the carrier state provides a continuous, long-term source of infectious virus. This is why venereal transmission is the dominant and most epidemiologically significant route for maintaining EAV in a population [13, 15, 20]. A single, undetected carrier stallion can infect a large number of mares during a single breeding season, and those mares, in turn, can horizontally transmit the virus to other horses via the respiratory route.

The evolution of EAV within the carrier stallion is not static. Deep sequencing studies have revealed that during persistent infection, the virus undergoes extensive genome-wide purifying selection driven by intrahost selective pressure, particularly within open reading frames ORF1a (nsp2), ORF3, and ORF5 [11]. This non-stochastic evolution suggests that distinct viral variants are selected for their ability to evade the immune response within the male reproductive tract while maintaining transmissibility [11]. This dynamic has practical implications, as the virus may evolve antigenic profiles that could, in theory, partially evade vaccine-induced immunity, although no evidence of such vaccine escape has yet been confirmed in the field. The potential for a single carrier stallion to give rise to a genetically diverse swarm of progeny virus that can be transmitted via semen to multiple mares makes it a potent engine of both viral perpetuation and evolution.

Indirect and Fomite Transmission

While direct contact is the primary transmission mechanism, EAV can be transmitted indirectly through fomites. Contaminated equipment such as semen collection artificial vaginas, syringes, needles, and grooming tools can mechanically transfer the virus [10]. The importance of this route is underscored by the fact that EAV, an enveloped virus, has a relatively short survival time in the environment under typical conditions but can remain infectious in semen and other body fluids for longer periods if kept cool and moist. The use of contaminated semen for artificial insemination is a well-documented and highly efficient route for introducing EAV into a naive herd, bypassing the need for animal movement and making international trade a major risk factor for viral introduction [14]. The control of this route is central to WOAH's recommendations for the international movement of equine semen, which require stallions to be either vaccinated or tested negative for EAV.

In summary, the epidemiology of EAV must be viewed through the lens of its carrier state. Global seroprevalence is a mosaic, reflecting local control efforts and the presence or absence of the viral reservoir. The primary risk factors are management practices that bring horses into contact and, most critically, the host’s genetic predilection (CXCL16 genotype) for becoming a carrier. The transmission dynamics pivot on the carrier stallion, which ensures the virus's long-term survival through venereal spread. Effective global control, therefore, hinges on identifying and managing these high-risk individuals, primarily through routine testing, strategic vaccination of colts, and strict biosecurity for all breeding stock, a fact that remains the central challenge in EVA epidemiology.

Clinical Manifestations and Pathology of Equine Viral Arteritis in Horses, Donkeys, and Mules

Equine viral arteritis (EVA) presents a remarkably broad clinical spectrum, ranging from clinically inapparent infections to a fulminant, systemic, and occasionally fatal disease. The manifestation of infection is governed by a complex interplay between the virulence of the infecting equine arteritis virus (EAV) strain, the age and immunological status of the host, and, critically, host genetic factors that influence both susceptibility to infection and the capacity to clear the virus. The disease is best characterized as a systemic, respiratory, and reproductive affliction of equids, with clinical signs reflecting the virus’s fundamental pathobiology: a primary endotheliotropism coupled with a profound capacity for immune modulation and evasion.

Clinical Spectrum in Horses

The majority of naturally acquired EAV infections in adult horses are subclinical or result in such mild, transient signs that they evade clinical detection. Estimates from serological surveys and outbreak investigations consistently indicate that inapparent infections constitute the majority of cases. For instance, the vast majority of infections are subclinical, yet acutely infected animals may develop a wide range of clinical signs [8]. This cryptic nature of infection is a major challenge for disease surveillance and control, as asymptomatic shedding can perpetuate transmission. When clinical disease does manifest, the incubation period following natural exposure (typically oronasal) ranges from 3 to 14 days. Experimentally, after nasal inoculation, signs can appear within 1 to 5 days.

The classic presentation of acute EVA in the horse is characterized by the sudden onset of pyrexia, which can be high (often exceeding 40°C / 104°F) and may persist for 2 to 9 days [8, 10]. This fever is frequently biphasic. Concurrently, a constellation of systemic signs emerges. A prominent and characteristic feature is the development of edema, most notably of the distal limbs (particularly the hindlimbs), the scrotum and prepuce in males, and the ventral abdomen and mammary gland in mares [12]. Supraorbital and periorbital edema is also a common and highly characteristic sign, contributing to a depressed, "sad" appearance.

Ocular and respiratory signs are hallmarks of the disease. Conjunctivitis is almost invariably present, ranging from mild serous discharge to severe chemosis and epiphora [8, 10]. Serous to mucopurulent nasal discharge is common. An urticarial-type skin rash may appear, particularly over the neck, trunk, and sides, often transiently. Anorexia and marked depression are consistently observed, reflecting the systemic nature of the illness. In severe cases, respiratory distress can progress to a fulminating interstitial pneumonia, a finding particularly noted in young foals [10, 12]. Gastrointestinal signs, including colic and diarrhea, are less common but can occur, and a pneumoenteritis syndrome has been described in foals [10].

Reproductive Pathology: Abortion and the Carrier State

The reproductive consequences of EAV infection are among the most economically devastating aspects of the disease and represent the primary drivers for control measures. In pregnant mares, infection can lead to abortion, typically occurring late in gestation (from approximately 3 to 10 months), though most commonly between 6 and 10 months [10, 12-14]. Abortion can occur during the acute phase of the illness or following an apparently mild or subclinical infection. The pathogenesis of abortion is not due to direct fetal infection in all cases but is rather a consequence of severe vasculitis and necrosis of the placenta, particularly the endometrium and chorionic villi. This vascular damage compromises the fetal-maternal interface, leading to hypoxia and fetal death. The fetus itself may be autolyzed or show minimal specific lesions. Infected foals that survive to term may be born weak and succumb to a rapidly progressive, fatal interstitial pneumonia shortly after birth.

Perhaps the most critical aspect of EAV pathogenesis from an epidemiological perspective is the establishment of the long-term carrier state in the stallion. Following natural infection, a variable but significant proportion (historically cited as 10-70%) of infected stallions fail to clear the virus and become persistently infected [6, 11, 13]. These carrier stallions shed EAV continuously in their semen for months or even years, often for life, without showing any clinical signs of infection during the carrier phase [10, 17]. This persistent infection is strictly confined to the reproductive tract, with the ampullae of the vas deferens identified as the primary site of viral persistence [11]. Crucially, the carrier state does not develop in mares, geldings, or sexually immature colts [10].

The Molecular Basis of Clinical Variability: Host Genetics and Viral Determinants

The profound individual variation in clinical outcome, particularly the susceptibility to becoming a long-term carrier, has been elegantly linked to host genetics. A landmark discovery identified that allelic variation in the equine orthologue of the chemokine CXCL16 is a critical determinant of this phenotype [9]. The protein CXCL16 functions as a cellular receptor for EAV on a subset of CD3+ T lymphocytes. Stallions possessing the susceptible alleles (CXCL16Sa or CXCL16Sb, together referred to as CXCL16S) have CD3+ T cells that are susceptible to in vitro EAV infection and are at significantly higher risk of establishing a long-term carrier state following natural infection [6, 9]. Conversely, the CXCL16R allele encodes a receptor variant that is non-functional for viral entry, conferring resistance at the cellular level and a drastically reduced probability of persistent infection. This dominant mode of inheritance provides a powerful tool for risk assessment; genotyping of prepubertal colts can identify those carrying the susceptible genotype, for whom vaccination is strongly recommended to prevent carrier establishment [6]. The biological mechanism links the expression of a host protein that is a viral receptor to a specific, epidemiologically critical clinical outcome.

Beyond host genetics, the intrinsic virulence of the infecting EAV strain dictates the severity of acute disease. While all EAV strains are considered to be of a single serotype, they exhibit marked variation in virulence. Highly virulent strains, such as the Bucyrus reference strain, induce severe, often fatal disease characterized by panvasculitis and extensive tissue necrosis, whereas other field strains may cause only mild or subclinical disease [16]. The molecular determinants of this virulence are under active investigation, but key genomic differences reside in the open reading frames (ORFs) encoding the structural glycoproteins (GP2, GP3, GP4, GP5) and non-structural proteins involved in immune evasion.

Clinical Disease in Donkeys and Mules

While the vast majority of the literature focuses on EAV in horses, infection in other equid species, donkeys (Equus asinus) and mules (Equus caballus × Equus asinus), is increasingly recognized. Serological evidence demonstrates that these species are susceptible to infection. Data from a large-scale European serosurvey (2011-2023) found an overall anti-EAV antibody prevalence of 7.7% in donkeys and 6.4% in mules/hinnies, confirming natural exposure [1]. Furthermore, this study provided the first documented detection of EAV seropositivity in mules/hinnies in Europe [1].

The clinical manifestations of EAV in donkeys and mules are generally considered to be milder and less defined than in horses. Clinical reports of naturally occurring EVA in these species are exceedingly rare. Most infections are believed to be subclinical or inapparent, with seropositive animals showing no history of clinical illness. When clinical signs do occur, they are thought to mirror the mild end of the spectrum seen in horses, perhaps transient pyrexia, mild depression, or slight conjunctivitis. The lack of robust clinical data, however, makes definitive characterization difficult. It remains an open question whether donkeys and mules can develop the full spectrum of severe disease, including abortion or the interstitial pneumonia syndrome. The economic and epidemiological significance of infection in these species likely lies in their potential role as silent reservoirs or sentinels for EAV circulation, rather than as primary clinical patients.

Pathology: The Endothelium as the Central Target

The pathological hallmarks of EVA are a direct consequence of the virus's profound tropism for vascular endothelial cells throughout the body. The primary lesion is a necrotizing arteritis and capillaritis affecting small- to medium-sized arteries [12]. This is most evident in the serosal and subserosal vessels of the intestinal tract, spleen, lymph nodes, and the reproductive tract.

Grossly, affected tissues exhibit characteristic changes. The vascular lesions are visible as hemorrhagic streaks and foci of necrosis, particularly on the serosal surfaces of the cecum and colon, giving a classic "paintbrush" or "fire streak" appearance. Edema of the subcutaneous tissues, especially in the distal limbs, prepuce, and scrotum, is a prominent macroscopic finding. The lungs may be heavy, edematous, and congested, particularly in foals with the pneumonic form. In aborted fetuses, there may be autolysis and minimal characteristic lesions, or evidence of placentitis.

Histologically, the hallmark is a necrotizing vasculitis. In the acute phase, the arterial media and adventitia are infiltrated by mononuclear cells (lymphocytes, macrophages) and neutrophils. There is severe edema of the vessel wall and necrosis of smooth muscle cells. Endothelial cells are swollen (hypertrophic) and may be hyperplastic or show frank necrosis and denudation. Fibrinoid necrosis of the vessel wall can occur, leading to thrombosis, ischemia, and infarction of downstream tissue. This damage underlies all the major clinical signs: edema from increased vascular permeability, hemorrhage from vessel wall rupture, and abortion from placental vascular insufficiency.

The virus also directly infects and replicates in macrophages and dendritic cells (DCs), which are crucial for initiating adaptive immunity. In vitro studies have demonstrated that EAV infection of monocytes and monocyte-derived dendritic cells (MoDCs) profoundly impairs their function. EAV replication leads to a downregulation of critical surface molecules (e.g., CD14, CD163 on monocytes; CD83 on mature DCs), inhibits endocytic and phagocytic capacity, and reduces the ability of infected DCs to stimulate T cell proliferation [5]. Ultimately, EAV replication induces apoptosis-mediated cell death in these immune cells [5, 18]. This targeted subversion of the antigen-presenting cell compartment is a sophisticated immune evasion strategy, effectively delaying the adaptive immune response and allowing for more extensive viral replication and dissemination during the critical early phase of infection. The virus further undermines host defenses by actively degrading the key signaling molecule MAVS (mitochondrial antiviral-signaling protein) via its non-structural protein 10 (nsp10), which recruits host E3 ubiquitin ligases (Smurf1 and MARCH5) to target MAVS for proteasomal destruction, thus dampening the interferon (IFN) response [4]. This combined strategy of suppressing innate immunity while undermining the bridge to adaptive immunity is central to the pathogenesis of EAV.

In summary, the clinical manifestations of EVA in horses span from subclinical to lethal, driven by a combination of viral virulence and host genetic susceptibility, particularly the CXCL16 genotype which dictates the risk of the carrier state. The pathology is rooted in a necrotizing panvasculitis, with the virus concurrently dismantling the host's immunological defenses. In donkeys and mules, infection appears predominantly subclinical, though they serve as important sentinels for viral circulation.

Diagnostic Approaches for EAV: Real-Time RT-PCR, Serological Assays, and Virus Isolation

The accurate and timely diagnosis of equine arteritis virus (EAV) infection is paramount for effective disease management, outbreak control, and international trade compliance. Given that EAV is a notifiable pathogen with substantial economic implications for the equine industry [1, 12], diagnostic strategies must be robust, sensitive, and capable of detecting infection across a spectrum of clinical presentations, from acute systemic disease to the clinically silent, yet epidemiologically critical, long-term carrier state in stallions. A multimodal diagnostic approach, integrating direct viral detection methods with serological profiling, remains the gold standard, as no single assay provides a complete picture of infection status. The World Organisation for Animal Health (WOAH) prescribes specific methodologies for official trade purposes, and the assays described herein are designed to align with these international standards, ensuring that surveillance data is comparable across borders.

Real-Time Reverse Transcription Polymerase Chain Reaction (Real-Time RT-PCR)

Real-time RT-PCR has emerged as the preeminent molecular diagnostic tool for the direct detection of EAV nucleic acid, offering unparalleled sensitivity, specificity, and speed. The assay is particularly valuable for detecting the virus in clinical samples where viral loads may be low or where the virus is labile, such as in semen, nasal swabs, and tissues from aborted fetuses. The foundational protocol, as described by Balasuriya et al. (2002) and validated in subsequent studies, typically targets a conserved 204-base pair segment within ORF7, which encodes the nucleocapsid (N) protein [21]. This region is highly conserved among diverse EAV strains, ensuring broad reactivity while minimizing the risk of false negatives due to genetic drift.

The diagnostic utility of real-time RT-PCR has been demonstrated across a variety of sample matrices. In a study applying the one-step protocol to 66 samples, including nasal swabs from mares, semen plasma from stallions, whole blood, and 10% tissue suspensions from aborted fetuses, the assay achieved a remarkable 96% positivity rate [21]. Only 0.5% of samples remained definitively negative upon re-testing, underscoring the method's robustness. The high sensitivity is further exemplified by its ability to detect viral RNA in semen, which is the primary vehicle for venereal transmission and maintenance of EAV in the population [2, 11]. Notably, the assay can be multiplexed with internal control targets to monitor for PCR inhibition, a critical consideration when working with complex biological fluids such as semen, which may contain inhibitory substances.

Beyond mere detection, real-time RT-PCR has been adapted for advanced molecular epidemiological and host-genetic studies. A particularly innovative application is the development of a TaqMan® allelic discrimination qPCR assay for genotyping the equine CXCL16 gene [6]. This assay specifically identifies a single nucleotide polymorphism (SNP) at position 1,073 in exon 2, which distinguishes the CXCL16^S (susceptible) and CXCL16^R (resistant) alleles. The CXCL16 S allele has been robustly associated with the establishment of the long-term carrier state in stallions, a phenomenon where up to 70% of infected stallions can persistently shed virus in their semen for years [6, 9]. By allowing breeders to genotype prepubertal colts, this assay facilitates a proactive management strategy: colts carrying the susceptible genotype (CXCL16^S/S or CXCL16^S/R) can be prioritized for vaccination after 6 months of age to prevent the establishment of the carrier state following natural infection [6]. This represents a paradigm shift from reactive diagnosis to predictive risk management, directly informing biosecurity and vaccination protocols.

The integration of real-time RT-PCR with next-generation sequencing (NGS) has further revolutionized our understanding of EAV evolution, particularly during persistent infection. Deep sequencing of sequential viruses isolated from the semen of carrier stallions has revealed that the initial virus populations in semen undergo a selective bottleneck, followed by extensive genome-wide purifying selection during persistence [11]. This non-stochastic intrahost evolution, driven by active selection pressure, predominantly affects ORF1a (encoding nsp2), ORF3, and ORF5 [11]. For the diagnostician, this means that the genomic targets used for RT-PCR assays must be carefully selected to avoid regions under high evolutionary pressure. The ORF7-based assays remain stable, but the broader implication is that molecular diagnostics must be periodically re-evaluated against circulating field strains. The 2019 UK outbreak investigations, for instance, utilized virus isolation coupled with full-genome sequencing to place strains within phylogroup D, demonstrating that molecular diagnostics are not static but must evolve alongside the pathogen [2].

Serological Assays: Virus Neutralization Test (VNT) and Enzyme-Linked Immunosorbent Assay (ELISA)

Serological assays are indispensable for determining prior exposure to EAV, monitoring vaccine responses, and conducting large-scale epidemiological surveys. The virus neutralization test (VNT) remains the gold standard serological method as prescribed by WOAH, owing to its high specificity and ability to quantify neutralizing antibody titers. The VNT measures the ability of serum antibodies to neutralize viral infectivity in cell culture, typically using RK-13 cells. Titers are expressed as the reciprocal of the highest serum dilution that completely inhibits cytopathic effect (CPE). This assay is critical for differentiating vaccinated from infected animals in some contexts and for assessing the immune status of stallions prior to breeding.

The VNT has been employed extensively in prevalence studies worldwide. In a study across the Vojvodina region of Serbia, 21.15% of 156 non-vaccinated horses tested seropositive by VNT, with titers ranging from 4 to over 128 [8]. Interestingly, the study identified a seropositive stallion that also tested positive for virus in his semen, highlighting the correlation between serological evidence of infection and the carrier state [8]. Similarly, a two-year longitudinal study in the same region using VNT demonstrated stable seroprevalence and seroconversion events within a single stable, confirming ongoing viral circulation [22]. In contrast, a VNT-based survey in the Orinoquia region of Colombia found zero positives among 100 horses, suggesting that EAV may still be exotic to that region [19]. These data illustrate the VNT's utility not only for individual animal diagnosis but also for mapping disease distribution and informing international movement restrictions.

While the VNT is specific, it is labor-intensive, requires cell culture facilities, and can take 3–5 days to yield results. Moreover, sera may exhibit cytotoxicity that interferes with the assay [8]. Consequently, enzyme-linked immunosorbent assays (ELISA) have been developed to provide higher throughput and faster turnaround times, particularly for large-scale surveillance. Indirect ELISAs, which detect anti-EAV antibodies (primarily IgG) using whole virus or recombinant antigens, have been validated against VNT and show strong correlation. A recent large-scale serosurvey across western Europe (Catalonia, Andalusia, and the UK) employed a commercial ELISA to test 1,425 equids, revealing an overall seroprevalence of 9.7% in unvaccinated animals [1]. This study detected significant regional variation, 15.6% in Catalonia versus 3.3% in the UK, and represented the first detection of EAV seropositivity in mules and hinnies in Europe [1]. The ELISA’s ability to process hundreds of samples rapidly makes it ideal for such cross-sectional studies, where the goal is to identify risk factors and exposure patterns rather than diagnose acute infection.

However, ELISA-based results must be interpreted with caution, as they cannot differentiate between antibodies induced by natural infection and those from vaccination. Furthermore, the presence of maternally derived antibodies in foals can confound results for up to 6–9 months. In contrast, the VNT can provide a more nuanced picture by measuring functional neutralizing antibodies, which are directly correlated with protective immunity. For instance, in vaccine efficacy studies, all 19 horses vaccinated with a modified-live virus developed serum-neutralizing antibodies, and 14 were completely protected from clinical disease upon challenge [23]. This direct measure of functional antibody is something ELISA cannot provide without specialized competitive formats.

Virus Isolation

Virus isolation remains an essential, albeit time-consuming, component of EAV diagnostics. It is the definitive method for confirming the presence of infectious virus and is indispensable for obtaining viral isolates for antigenic characterization, vaccine matching, and phylogenetic analysis. The permissive cell lines of choice include rabbit kidney (RK-13), baby hamster kidney (BHK-21), Vero, and primary equine endothelial cells, with RK-13 being the most widely used due to its robust and characteristic cytopathic effect (CPE) [16, 18]. The choice of cell line can influence diagnostic outcomes; for example, while all strains produce comparable CPE in RK-13 cells, virulent and avirulent strains can be distinguished by their plaque morphology and cytopathogenicity in primary equine pulmonary artery endothelial cells [16]. This differential growth is predictive of virulence in vivo, making virus isolation not just a detection tool but also a phenotypic characterization assay.

The protocol typically involves inoculating clarified clinical samples (e.g., semen, nasal swab eluates, tissue homogenates) onto confluent monolayers and observing for CPE over 3–7 days. Positive cultures exhibit cell rounding, detachment, and syncytia formation. The identity of the isolate is then confirmed by immunofluorescence or RT-PCR. The sensitivity of virus isolation is generally lower than that of RT-PCR, particularly for samples with low viral loads or those that have been improperly stored, as EAV is thermolabile. Despite this, isolation remains critical for characterizing outbreak strains. In the 2019 UK outbreaks, virus isolation from clinical samples allowed for full-genome sequencing, which revealed a unique truncation in the GP4 protein at position 149, a feature not previously identified in any arterivirus [2]. Such discoveries are impossible with PCR alone.

The kinetics of viral replication in vitro also provide insights into pathogenesis. Studies have shown that EAV induces apoptosis in infected cells, but the pathway and timing are cell-line dependent. In RK-13 cells, DNA fragmentation (a hallmark of apoptosis) is detectable at 48 hours post-infection, whereas in BHK-21 cells, it is delayed until 96 hours [18]. This differential induction of caspase-dependent cell death influences viral titers, as apoptosis can interfere with viral replication [18]. For diagnostic purposes, understanding these kinetics is crucial for determining the optimal harvest time for virus isolation. Furthermore, the recent identification of CD81 as an essential entry receptor for EAV [3] opens new avenues for improving isolation protocols. Supplementing cell culture media with soluble CD81 or using knockout cell lines could provide novel tools for enhancing or blocking viral entry, respectively, though such applications remain experimental. The use of equine dermal cells (E. Derm, NBL-6) has also been successful for vaccine propagation and could be adapted for diagnostic isolation, particularly for strains adapted to growth in this cell line [23].

The triad of real-time RT-PCR, serology, and virus isolation provides a comprehensive diagnostic framework. RT-PCR offers speed and sensitivity for direct viral detection, serology reveals the history of infection and immune status, and virus isolation provides the live virus necessary for definitive characterization. The judicious application of these methods, guided by the clinical context, sample type, and epidemiological objectives, is essential for controlling EAV and preventing the silent spread of this economically devastating pathogen.

Prevention and Control Strategies for Equine Viral Arteritis: Vaccination, Biosecurity, and Regulatory Measures

The control of equine viral arteritis (EVA) represents a singular challenge in veterinary medicine, one that demands a coordinated interplay between immunological intervention, rigorous biosecurity protocols, and transparent regulatory frameworks. The pathogen’s capacity to establish a long-term carrier state in stallions, its predominantly subclinical transmission dynamics, and its economic repercussions on international equine commerce necessitate a multilayered prevention strategy. This section dissects the current and emerging approaches to EVA prevention and control, examining the mechanistic underpinnings of vaccination, the practical exigencies of biosecurity, and the critical role of national and international regulatory oversight.

Vaccination Strategies: Immunological Foundations and Practical Application

Vaccination remains the cornerstone of proactive EVA control, yet its deployment is nuanced by the virus's unique biology and the host's genetic predisposition to persistent infection. The only commercially available vaccines globally are modified-live virus (MLV) formulations, derived from the experimental ARVAC strain. The foundational work by McCollum demonstrated that an avirulent live-virus vaccine, passaged extensively through equine and rabbit kidney cells before adaptation to an equine dermis cell line (EAV HK-131/RK-111/ED-16), could be administered intramuscularly without inducing clinical disease [23]. This vaccine proved remarkably safe, eliciting robust serum-neutralizing antibodies in all inoculated horses. Crucially, protection against severe clinical arteritis following nasal challenge with virulent virus was demonstrable for at least 24 months post-vaccination, with vaccinated horses exhibiting transient thermal reactions and shorter virus persistence compared to non-vaccinated controls [23]. However, a critical biological caveat emerged: vaccination did not prevent infection per se. All vaccinated horses, even those completely protected from clinical signs, became infected upon challenge and mounted a secondary humoral immune response, with virus recovery possible from the majority [23]. This finding underscores that the MLV vaccine protects against disease, not against infection or subsequent viral shedding, a distinction with profound implications for herd-level control.

The efficacy of MLV vaccination is further contextualized by the discovery of host genetic determinants of persistence. The seminal work by Sarkar et al. and subsequent developments by Thieulent et al. identified allelic variation in the equine CXCL16 gene as the primary genetic regulator of the long-term carrier state in stallions [6, 9]. The CXCL16S allele encodes a protein isoform that functions as a cellular receptor for EAV on CD3+ T lymphocytes, rendering stallions with at least one copy of this allele (genotypes CXCL16 S/S or CXCL16 S/r) highly susceptible to establishing persistent infection in the reproductive tract. Conversely, stallions homozygous for the CXCL16R allele are significantly less likely to become long-term carriers [6, 9]. This discovery has revolutionized vaccination strategy, particularly for prepubertal colts. The TaqMan® allelic discrimination qPCR assay now permits the rapid genotyping of young colts, identifying those carrying the susceptible genotype. It is now a recommended best practice to vaccinate susceptible colts after six months of age, thereby preventing the establishment of the carrier state should they encounter natural infection later in life [6]. This targeted approach moves beyond blanket vaccination toward precision veterinary immunoprophylaxis, directly disrupting the virus's primary maintenance reservoir.

Despite the proven utility of the MLV vaccine, significant gaps in global vaccination coverage persist, as highlighted by Valle-Casuso et al., who noted that coverage is "largely insufficient to prevent new EAV outbreaks around the world" [24]. This inadequacy is partly logistical, vaccination is not universally mandated, and partly biological, stemming from the vaccine's inability to confer sterilizing immunity. The virus's intrahost evolution during persistent infection, characterized by purifying selection and non-stochastic mutations in ORF1a (nsp2), ORF3, and ORF5, raises theoretical concerns about the emergence of vaccine-escape variants, although none have been conclusively documented [11]. The future of EAV vaccination may lie in the development of next-generation vaccines, including subunit vaccines targeting the newly identified CD81 receptor binding domain or replicon particles capable of inducing broader mucosal and cytotoxic T-cell responses [3]. Furthermore, the identification of antiviral compounds such as ribavirin and inhibitors of dihydroorotate dehydrogenase (DHODH), which suppress EAV replication in vitro, opens the possibility of therapeutic vaccination or chemoprophylaxis during outbreaks, though these remain experimental [24].

Biosecurity Measures: Interrupting Transmission Chains

Biosecurity for EVA must be intelligently designed around the virus's primary transmission routes: venereal shedding in the semen of carrier stallions and aerosolization of respiratory secretions during acute infection. The carrier stallion is unequivocally the most significant epidemiological threat, serving as the sole natural reservoir and perpetuating the virus within the equine population [13, 17, 20]. Consequently, the most critical biosecurity intervention is the rigorous screening of breeding stallions. Real-time RT-PCR assays targeting the ORF7 segment, as validated by Chenchev et al., provide a sensitive and rapid method for detecting EAV RNA in semen plasma, nasal swabs, and whole blood, with a demonstrated sensitivity of 96% in clinical samples [21]. Sequential testing of semen from all breeding stallions, ideally prior to the breeding season and following any quarantine period, is non-negotiable. Stallions identified as shedders must be permanently segregated from non-immune mares, or their breeding restricted exclusively to mares that have been either vaccinated or have naturally acquired immunity [20].

The management of acutely infected horses requires equally stringent protocols. During the febrile and respiratory phase, EAV is shed profusely in nasal secretions and is highly contagious via aerosol and fomite transmission. Affected horses must be isolated in dedicated facilities with separate air handling, and personnel must employ barrier nursing techniques, including the use of dedicated equipment and footwear. The virus's ability to induce apoptosis in dendritic cells and monocytic cells, thereby impairing antigen presentation and facilitating immune evasion, underscores the importance of early detection and intervention to prevent widespread dissemination [5, 18]. Biosecurity protocols must also extend to vector control, as risk factor analyses from Turkey have identified that precautions taken against rodents and insects at enterprises are statistically correlated with EAV infection status, although the precise mechanical or biological vector role remains unclear [7].

At the population level, serological surveillance forms the backbone of biosecurity planning. The heterogenous seroprevalence patterns observed across Europe, ranging from 3.3% in the UK to 15.6% in Catalonia and 21.15% in regions of Serbia, indicate that biosecurity measures must be tailored to the local epidemiological context [1, 8]. High-risk regions, characterized by dense horse populations, frequent movement for competitions or breeding, and a history of EAV circulation, should implement mandatory pre-movement testing and quarantine. The World Organisation for Animal Health (WOAH) guidelines recommend that any horse imported into a country or region from an EAV-endemic area should present a negative RT-PCR result from a semen sample (for stallions) or serological evidence of vaccination or prior exposure. Countries currently free of EAV, such as Colombia based on serosurveys from the Orinoquia region, must maintain stringent import controls to preserve their status [14, 19].

Regulatory Measures: The Architecture of International Control

The regulatory landscape for EVA is defined by its status as a notifiable disease in many jurisdictions, a designation that carries significant legal and trade implications. The economic impact of EVA is driven not only by direct losses from abortion and mortality but also by the indirect costs of trade restrictions [14]. Stallions that test positive for EAV shedding face permanent restrictions on the export of their semen and may be barred from entering certain countries or breeding facilities. This regulatory reality creates a powerful economic incentive for control, yet it also disincentivizes testing in some sectors, a paradox that must be addressed through harmonized international standards.

The WOAH Terrestrial Animal Health Code provides the framework for international trade in equids and their germplasm. The Code stipulates that semen from a stallion must be collected from an animal that has not shown clinical signs of EVA for a specified period and that has tested negative for EAV by virus isolation or RT-PCR on semen. Alternatively, if the stallion is seropositive, it must have been vaccinated at least 21 days before semen collection, and the semen must be free of EAV. These regulations, while scientifically sound, place the onus on exporting countries to maintain rigorous surveillance and diagnostic capacity. The European Union, for its part, has faced challenges in harmonizing EVA control across member states, as vaccination policies and seroprevalence rates vary widely [1]. The recent phylodynamic analyses of the 2019 UK outbreaks, which traced viral introduction via imported infected horses and demonstrated bidirectional transmission between infected and susceptible animals, highlight the inadequacy of fragmented regulatory systems [2].

An effective regulatory framework must therefore integrate several key components: mandatory reporting of acute cases, compulsory testing of all breeding stallions, traceability of equine movements, and a clear legal status for vaccinated animals. The identification of CXCL16 genotypes as a predictor of carrier risk opens the door for genotype-informed regulatory policies. For example, regulators could require that stallions with the susceptible CXCL16 S/S or S/r genotype be vaccinated as a condition of breeding licensing, whereas those with the resistant r/r genotype might be exempted from vaccination but still subject to regular PCR testing [6, 9]. Such nuance would optimize resource allocation and minimize unnecessary restrictions on low-risk animals. Moreover, regulatory bodies must fund and coordinate ongoing genomic surveillance to detect the emergence of novel variants, particularly those with mutations in GP2, GP3, GP4, or GP5, which could alter antigenicity or pathogenicity [2]. Only through a cohesive, science-based regulatory architecture can the cycle of transmission from carrier stallion to susceptible mare to abortion and further dissemination be definitively broken.

References

[1] Franco JJ, Gonzálvez M, Cano‐Terriza D, Barbero-Moyano J, Jose-Cunilleras E, Alguacil E, et al.. Equine viral arteritis: Seroprevalence patterns and risk factors in equids from western Europe.. Research in Veterinary Science. 2025. DOI: https://doi.org/10.1016/j.rvsc.2025.105701

[2] Bhat S, Karunakaran S, Frossard J, Choudhury B, Steinbach F. Genetic characterization of equine arteritis virus associated with outbreaks in the UK, 2019. Journal of General Virology. 2025. DOI: https://doi.org/10.1099/jgv.0.002181

[3] Maloney SM, Shaw TM, Nennig K, Larsen MS, Shah AP, Kumar A, et al.. CD81 is a receptor for equine arteritis virus (family: Arteriviridae). mBio. 2025. DOI: https://doi.org/10.1128/mbio.00623-25

[4] Zhou B, Chen K, Liang H, Qi T, Guo X, Wen Y, et al.. Equine arteritis virus Nsp10 promotes MAVS proteasomal degradation via E3 ligases Smurf1/MARCH5. Journal of Virology. 2026. DOI: https://doi.org/10.1128/jvi.02061-25

[5] Moyo N, Westcott D, Simmonds R, Steinbach F. Equine Arteritis Virus in Monocytic Cells Suppresses Differentiation and Function of Dendritic Cells. Viruses. 2023. DOI: https://doi.org/10.3390/v15010255

[6] Thieulent CJ, Carossino M, Balasuriya UBR, Graves K, Bailey E, Eberth J, et al.. Development of a TaqMan® Allelic Discrimination qPCR Assay for Rapid Detection of Equine CXCL16 Allelic Variants Associated With the Establishment of Long-Term Equine Arteritis Virus Carrier State in Stallions. Frontiers in Genetics. 2022. DOI: https://doi.org/10.3389/fgene.2022.871875

[7] Ince O, Şevik M. Equine arteritis virus seroprevalence and risk factors in horses in the inner Aegean and Central Anatolia regions of Turkey. Journal of the Hellenic Veterinary Medical Society. 2022. DOI: https://doi.org/10.12681/jhvms.26849

[8] Gaudaire D, Lupulović D, Savić S, Chevé F, Lecouturier F, Lazić G, et al.. Evidence of Equine Viral Arteritis (EVA) infection in horses of Serbia. Journal of Equine Veterinary Science. 2016. DOI: https://doi.org/10.1016/J.JEVS.2016.02.125

[9] Sarkar S, Bailey E, Go Y, Cook R, Kalbfleisch T, Eberth J, et al.. Allelic Variation in CXCL16 Determines CD3+ T Lymphocyte Susceptibility to Equine Arteritis Virus Infection and Establishment of Long-Term Carrier State in the Stallion. PLoS Genetics. 2016. DOI: https://doi.org/10.1371/journal.pgen.1006467

[10] Ge M, Mm A, R FC, I C, Fa O, Mg E. Equine arteritis virus cytopathic effect: caspase-dependent cell death as the major consequence observed. Journal of Microbiology & Experimentation. 2018. DOI: https://doi.org/10.15406/JMEN.2018.06.00210

[11] Nam B, Mekuria ZT, Carossino M, Li G, Zheng Y, Zhang J, et al.. Intrahost Selection Pressure Drives Equine Arteritis Virus Evolution during Persistent Infection in the Stallion Reproductive Tract. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.00045-19

[12] Piero FD, Wilkins PA. Equine Viral Arteritis. Current Therapy in Equine Medicine. 2009. DOI: https://doi.org/10.1016/B978-0-7216-9540-2.50015-3

[13] Timoney P, McCollum W. Equine Viral Arteritis. The Veterinary clinics of North America. Equine practice. 1993. DOI: https://doi.org/10.1016/S0749-0739(17)30397-8

[14] Ruíz-Sáenz J. Equine Viral Arteritis: epidemiological and intervention perspectives. Revista Colombiana de Ciencias Pecuarias. 2010. DOI: https://doi.org/10.17533/udea.rccp.324613

[15] Balasuriya U, Go Y, Maclachlan N. Equine arteritis virus. Veterinary Microbiology. 2013. DOI: https://doi.org/10.1016/j.vetmic.2013.06.015

[16] Moore BD, Balasuriya U, Hedges JF, Maclachlan N. Growth characteristics of a highly virulent, a moderately virulent, and an avirulent strain of equine arteritis virus in primary equine endothelial cells are predictive of their virulence to horses.. Virology. 2002. DOI: https://doi.org/10.1006/VIRO.2002.1466

[17] Chirnside ED. Equine arteritis virus: An overview. British Veterinary Journal. 1992. DOI: https://doi.org/10.1016/0007-1935(92)90044-2

[18] Metz G, Abeyá M, Serena M, Panei C, Echeverría M. Evaluation of apoptosis markers in different cell lines infected with equine arteritis virus. Biotechnic & Histochemistry. 2018. DOI: https://doi.org/10.1080/10520295.2018.1521989

[19] AgustínGóngora O, Barrandeguy M. Serological survey for equine viral arteritis in several municipalities in the Orinoquia region of Colombia Monitoreo serológico de arteritis viral equina en municipios de la Orinoquia, Colombia. . 2014. DOI: https://doi.org/10.21897/RMVZ.89

[20] Timoney P, McCollum W, Aw R, Mj M. Status of equine viral arteritis in Kentucky, 1985.. Journal of the American Veterinary Medical Association. 1987. DOI: https://doi.org/10.2460/javma.1987.191.01.36

[21] Chenchev I, Polychronova L, Chakarova S, Genova I. REAL-TIME PCR FOR DETECTION OF EQUINE ARTERITIS VIRUS. . 2010. DOI: https://doi.org/10.46784/e-avm.v3i1.189

[22] Lazić S, Lupulović D, Lazić G, Živulj A, Bugarski D, Petrović T. STUDY OF THE EQUINE VIRAL ARTERITIS SEROCONVERSION AT HORSE STABLES IN THE TERRITORY OF VOJVODINA. . 2014. DOI: https://doi.org/10.46784/E-AVM.V6I2.151

[23] Wh M. Responses of horses vaccinated with avirulent modified-live equine arteritis virus propagated in the E. Derm (NBL-6) cell line to nasal inoculation with virulent virus.. American Journal of Veterinary Research. 1986. DOI: https://doi.org/10.2460/ajvr.1986.47.09.1931

[24] Valle-Casuso J, Gaudaire D, Martin-Faivre L, Madeline A, Dallemagne P, Pronost S, et al.. Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors. bioRxiv. 2020. DOI: https://doi.org/10.1038/s41598-020-66944-4